Ubrelvy (ubrogepant) was the first oral CGRP receptor antagonist approved for the acute treatment of migraine in adults. What you need to know now, especially if you can't take triptans.

Traws Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, announced the dosing of the first ...

Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment ...

COVID-19 is rising in prevalence in many states nationally after the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid — is less clear. Research studies ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate. Clinical ...

DEAR DR. ROACH: I foolishly was in a crowded indoor location and got COVID (for the third time). I thought about getting Paxlovid. But I figured, heck, I’m healthy and vaccinated; I’ll just tough it ...

Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests. Paxlovid - Pfizer ...

Most of us are pretty adept by now at managing COVID-19, with an armor of past infections, vaccinations, self-tests, and antiviral medications like Paxlovid. In the latest study, however, researchers ...

Please provide your email address to receive an email when new articles are posted on . Paxlovid may not decrease the risk for hospitalization or death among older adults who are vaccinated.

Paxlovid, one of the most well-known treatments for COVID-19, has also been shown to ease symptoms of some patients with long COVID — and new research suggests the antiviral medication could prove to ...